There are a series of notable events touching on Edwards Lifesciences Corporation (EW). Analysts tout Edwards Lifesciences as a growth stock, driving a recent rally in the market. This follows a series of positive achievements, including securing FDA approval for their groundbreaking TAVR therapy for asymptomatic patients and a latest price target increase to $95. Robust financials and strong sales growth, especially in TMTT sales, have been significant drivers of this stellar performance. Additionally, investors are awaiting the company's Q1 2025 earnings with Wall Street estimates promising a favourable picture.
However, the company is facing a potential securities fraud, drawing considerable legal attention. This has ironically been signposted alongside the planned presentation at BofA Securities Health Care Conference and hosting of a critical earnings conference. Edwards Lifesciences also recently sold Critical Care and has cited weak expectations for its primary moneymaker. Despite these challenges, the company remains bullish, underlined by its strong Q1 2025 results beating EPS forecast and impressive aortic valve study results.
Edwards Lifesciences Corp EW News Analytics from Mon, 15 Jul 2024 07:00:00 GMT to Sat, 24 May 2025 20:08:53 GMT - Rating 6 - Innovation 5 - Information 7 - Rumor 5
